^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Renal Cell Carcinoma

    Related cancers:
    1d
    KEYNOTE A99: Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) (clinicaltrials.gov)
    P1/2, N=296, Active, not recruiting, Inhibrx Biosciences, Inc | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden)
    |
    EGFR mutation • TMB-H • MSI-H/dMMR • ALK rearrangement
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • ordastobart (INBRX-106)
    1d
    Patient Navigation Program to Improve Clinical Trial Enrollment in Cancer Patients (clinicaltrials.gov)
    P=N/A, N=90, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Not yet recruiting --> Recruiting
    Enrollment open
    1d
    Integrating whole-exome sequencing and scRNA-seq reveal the characteristic in one clear cell renal cell carcinoma sample arising in the setting of VHL disease. (PubMed, Sci Rep)
    In addition, we discovered the relationship between genetic mutations and immune checkpoints. This work highlights the single-cell transcriptome and DNA-level information of this rare ccRCC and will provide more genetic insights and references into this rare disease.
    Journal
    |
    BCR (BCR Activator Of RhoGEF And GTPase) • VHL (von Hippel-Lindau tumor suppressor)
    |
    VHL mutation
    1d
    Establishment of patient-derived 3D tumouroids: personalised medicine tools for renal cancer. (PubMed, Acta Biomater)
    Finally, tumouroids were subjected to treatment with Pazopanib (Votrient™), a tyrosine kinase inhibitor (TKI) used in the treatment of advanced RCC...Tumouroids mimic the original tumour and its microenvironment and elicit response to drugs that target both the tumour cells and the tumour microenvironment. This is a patient-specific in vitro tool that addresses the unmet clinical need for predicting an individual's response to therapy.
    Journal
    |
    CA9 (Carbonic anhydrase 9)
    |
    pazopanib
    2d
    Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=44, Completed, Bristol-Myers Squibb | Terminated --> Completed
    Trial completion
    |
    Opdivo (nivolumab) • Erbitux (cetuximab)
    2d
    High Frequency and Unique Subtypes of Meningioma in Patients with BAP1 Tumor Predisposition Syndrome. (PubMed, medRxiv)
    Patient and family cancer history included other BAP1 -TPDS associated cancers, but only three patients had relatives with meningioma. Our findings indicate a need for routine craniospinal imaging in BAP1 -TPDS patients, and surveillance should include patients without family history of meningioma and patients under the age of 30.
    Journal
    |
    BAP1 (BRCA1 Associated Protein 1)
    2d
    TFE3-rearranged renal cell car cinoma with massive calcification: Imaging-pathologic correlation. (PubMed, J Clin Imaging Sci)
    Here, we report a case of TFE3-rearranged RCC with extensive calcification in a young female, emphasizing imaging-pathologic correlation to enhance diagnostic accuracy. This case underscores the importance of recognizing atypical radiological features in rare RCC subtypes.
    Journal
    |
    TFE3 (Transcription Factor Binding To IGHM Enhancer 3)
    2d
    Co-occurrence of peritoneal mesothelioma and genitourinary cancers: a case series with comparative outcomes. (PubMed, Pleura Peritoneum)
    These findings raise the hypothesis of a potential association between PM and GU malignancy. Shared origins, oncogenesis of similar cell types, environmental exposures or genetic predispositions may contribute and warrant further investigation.
    Journal
    |
    BAP1 (BRCA1 Associated Protein 1)
    2d
    Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers (clinicaltrials.gov)
    P2, N=45, Active, not recruiting, Dana-Farber Cancer Institute | Trial primary completion date: Nov 2025 --> Jul 2025
    Trial primary completion date
    |
    SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab)
    2d
    High Protein, Core Muscle Rehab, Muscular Electrostimulation in Prolonged Mechanical Ventilation (clinicaltrials.gov)
    P=N/A, N=100, Completed, Chang Gung Memorial Hospital | Recruiting --> Completed
    Trial completion
    2d
    Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=130, Recruiting, Sairopa B.V. | N=90 --> 130 | Trial completion date: Dec 2025 --> Jul 2027 | Trial primary completion date: Dec 2025 --> May 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • ADU-1805
    2d
    Randomized Clinical Trial Aimed at Comparing Unclamped Robotic Partial Nephrectomy With or Without Renorrhaphy (clinicaltrials.gov)
    P=N/A, N=248, Active, not recruiting, Regina Elena Cancer Institute | Trial primary completion date: Jul 2025 --> Jul 2028 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial primary completion date